drug · small molecule
cabozantinib s-malate
Marketedupdated 4mo agoby $EXEL EXELIXIS, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugCABOMETYX97 co-mentions · 25 sources
- drugCOMETRIQ97 co-mentions · 25 sources
- tagApproval96 co-mentions · 24 sources
- drugcabozantinib48 co-mentions · 24 sources
- tagSmall Molecule48 co-mentions · 24 sources
- tagOncology2 co-mentions · 1 sources
- company$TAKTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
- company$TKPHFTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 9 investigational indications.
targets
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
all catalysts(25)
approval · 24
Nov 29, 2012
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Feb 28, 2014
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Apr 25, 2016
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
May 20, 2016
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Oct 5, 2017
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Nov 16, 2017
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Dec 19, 2017
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jan 12, 2018
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jan 14, 2019
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jan 31, 2020
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jan 31, 2020
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jul 16, 2020
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Oct 22, 2020
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Nov 5, 2020
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jan 22, 2021
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Sep 17, 2021
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Jul 14, 2022
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Feb 13, 2023
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Aug 23, 2023
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Sep 20, 2023
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Mar 26, 2025
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Sep 10, 2025
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Oct 9, 2025
approval
$EXEL58.53+2.88%
CABOMETYX (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Oct 9, 2025
approval
$EXEL58.53+2.88%
COMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
cabozantinib s-malate
→
Trials studying cabozantinib s-malate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 17, 2028
~2.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (46)
- Jul 9, 2033formulationUS 9724342
- Jul 9, 2033formulationUS 9724342
- Jul 9, 2033formulationUS 9724342
- Feb 10, 2032formulationUS 11298349
- Feb 10, 2032formulationUS 11298349
- Feb 10, 2032formulationUS 11298349
- Feb 10, 2032formulationUS 11298349
- Feb 10, 2032formulationUS 11298349
- Feb 10, 2032formulationUS 12128039
- Feb 10, 2032formulationUS 12128039
- Feb 10, 2032formulationUS 12128039
- Feb 10, 2032formulationUS 12128039
- Feb 10, 2032formulationUS 12128039
- Feb 10, 2032formulationUS 9717720
- Feb 10, 2032formulationUS 9717720
- Jul 18, 2031method-of-use (U-2488)US 100348734.9y
- Jul 18, 2031method-of-use (U-2488)US 100348734.9y
- Jul 18, 2031method-of-use (U-2488)US 100348734.9y
- Jul 18, 2031method-of-use (U-1480)US 100397574.9y
- Jul 18, 2031method-of-use (U-1480)US 100397574.9y
- Jul 18, 2031method-of-use (U-1480)US 100397574.9y
- Oct 8, 2030compositionUS 88777764.1y
- Oct 8, 2030compositionUS 88777764.1y
- Oct 8, 2030compositionUS 88777764.1y
- Oct 8, 2030compositionUS 88777764.1y
- Oct 8, 2030compositionUS 88777764.1y
- Jan 15, 2030compositionUS 110914393.4y
- Jan 15, 2030compositionUS 110914393.4y
- Jan 15, 2030compositionUS 110914393.4y
- Jan 15, 2030compositionUS 110914393.4y
- Jan 15, 2030compositionUS 110914393.4y
- Jan 15, 2030formulationUS 110914403.4y
- Jan 15, 2030formulationUS 110914403.4y
- Jan 15, 2030formulationUS 110914403.4y
- Jan 15, 2030formulationUS 110914403.4y
- Jan 15, 2030formulationUS 110914403.4y
- Jan 15, 2030method-of-use (U-1617)US 110980153.4y
- Jan 15, 2030method-of-use (U-1617)US 110980153.4y
- Jan 15, 2030method-of-use (U-3225)US 110980153.4y
- Jan 15, 2030method-of-use (U-3225)US 110980153.4y
- Jan 15, 2030method-of-use (U-3225)US 110980153.4y
- Aug 14, 2026compositionUS 7579473
- Aug 14, 2026compositionUS 7579473
- Aug 14, 2026compositionUS 7579473
- Aug 14, 2026compositionUS 7579473
- Aug 14, 2026compositionUS 7579473
FDA exclusivities (6)
- Sep 17, 2028ODE-375Orphan Drug (7y)2.0y
- Sep 17, 2028ODE-375Orphan Drug (7y)2.0y
- Sep 17, 2028ODE-375Orphan Drug (7y)2.0y
- Jan 14, 2026ODE-227Orphan Drug (7y)
- Jan 14, 2026ODE-227Orphan Drug (7y)
- Jan 14, 2026ODE-227Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that